556508Department of Pediatrics Hematology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, China.
556508Children Hematological Oncology and Birth Defects Laboratory, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, China.
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211065877. doi: 10.1177/15330338211065877.
VAV family genes ( and ) are associated with prognosis in various cancers; however, they have not been evaluated in acute myeloid leukemia (AML). In this study, the prognostic value of VAV expression in AML was evaluated by a single-center study in combination with bioinformatics analyses. The expression and prognostic value of VAVs in patients with AML were investigated using various databases, including GEPIA, CCLE, EMBL-EBI, UALCAN, cBioPortal, STRING, and DAVID. Blood samples from 35 patients with AML (non-M3 subtype) and 13 benigh individuals were collected at our center. VAV expression levels were detected by real-time quantitative PCR (RT-qPCR) and western blotting. Clinical data were derived from medical records. Based on data from multiple databases, the expression levels of VAV1, VAV2, and VAV3 were significantly higher in AML than in control tissues ( < 0.05). RT-qPCR and western blotting results showed that expression in mRNA and protein levels were higher in patients with AML that in the control group ( < 0.05). Complete remission rates were lower and risks were higher in patients with AML with high expression than with low expression ( < 0.05). High levels of VAV2, VAV3, and VAV1 were related to a poor overall survival, and this relationship was significant for VAV1 ( < 0.05). High expression levels of genes correlated with , such as , , and were also related to a poor prognosis in AML. Functional and pathways enrichment analyses indicated that the contribution of the VAV family to AML may be mediated by the NF-κB, cAMP, and other pathways. VAVs were highly expressed in AML. In particular, VAV1 has prognostic value and is a promising therapeutic target for AML.
VAV 家族基因（和）与各种癌症的预后相关；然而，它们在急性髓系白血病（AML）中尚未得到评估。在这项研究中，通过单中心研究结合生物信息学分析评估了 VAV 表达在 AML 中的预后价值。使用包括 GEPIA、CCLE、EMBL-EBI、UALCAN、cBioPortal、STRING 和 DAVID 在内的各种数据库研究了 AML 患者中 VAV 的表达及其预后价值。从本中心收集了 35 名 AML（非 M3 亚型）患者和 13 名良性个体的血液样本。通过实时定量 PCR（RT-qPCR）和 Western blot 检测 VAV 表达水平。临床数据来自病历。基于多个数据库的数据，VAV1、VAV2 和 VAV3 的表达水平在 AML 中明显高于对照组织（<0.05）。RT-qPCR 和 Western blot 结果表明，VAV 在 mRNA 和蛋白水平上的表达在 AML 患者中高于对照组（<0.05）。VAV 高表达的 AML 患者完全缓解率较低，风险较高（<0.05）。VAV2、VAV3 和 VAV1 水平高与总生存期较差相关，VAV1 的这种关系具有统计学意义（<0.05）。与基因相关的表达水平，如、和，也与 AML 的不良预后相关。功能和途径富集分析表明，VAV 家族对 AML 的贡献可能是通过 NF-κB、cAMP 等途径介导的。VAV 在 AML 中高度表达。特别是，VAV1 具有预后价值，是 AML 的有前途的治疗靶点。
